Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
For informational and educational purposes only. Not FDA-approved for human use. Consult a licensed healthcare professional. See full disclaimer.
LL-37 Dosage Guide: Recommended Protocol & Cycle Length
Typical LL-37 dosage ranges from 50–500 mcg depending on route and application. Topical/local: 100–500 mcg applied directly to wound or injection site. Intranasal: 50–100 mcg per nostril. Systemic injection: 50–100 mcg subcutaneous or intramuscular. Start conservatively, titrate based on response. Always follow supplier guidelines and medical supervision.
What Is the Recommended LL-37 Dosage?
Recommended dosage varies significantly by route and application: Topical (wound/skin): 100–500 mcg applied directly. Intranasal (sinus/respiratory): 50–100 mcg per nostril, 1–2x daily. Subcutaneous (systemic immune): 50–100 mcg, 3–5x weekly. Intramuscular (systemic immune): 50–100 mcg, 3–5x weekly. Local injection (biofilm/infection): 100–250 mcg, 3–7x weekly. Dosing depends on peptide concentration, potency, and individual factors. Start lower, titrate based on response and tolerance.
Dosage by Application (Topical, Injection, Systemic)
Topical: 100–500 mcg applied to wound, allowed to dry or covered. Can be applied daily. Subcutaneous: 50–100 mcg with insulin syringe into abdomen or thigh. Intramuscular: 50–100 mcg into glute or deltoid. Intranasal: 50–100 mcg sprayed into each nostril. Rectal: 100–300 mcg via suppository or retention enema. Route selection depends on desired effect—local for wound healing, systemic for immune support.
Dosing for Wound Healing
Acute wound: 100–250 mcg topical applied 1–2x daily until closure. Chronic wound (diabetic ulcer, pressure ulcer): 200–500 mcg topical daily or local injection 3–7x weekly. Surgical wound: 100–200 mcg topical daily for 2–4 weeks post-op. Combine with standard wound care protocols. Higher doses tolerate better for local application than systemic injection.
Dosing for Immune Support
Systemic immune: 50–100 mcg subcutaneous or intramuscular, 3–5x weekly for 4–8 weeks. Can be stacked with other immune peptides (lower individual doses when stacking). Start at lower end (50 mcg), increase if needed. Some protocols use daily dosing for acute illness (2–4 weeks), then taper to maintenance (2–3x weekly).
Dosing for Biofilm Disruption
Chronic biofilm infection: 100–250 mcg local injection or topical application, 3–7x weekly combined with antibiotics. Higher concentrations (250+ mcg) more effective for biofilm than lower doses. Local application preferable to systemic for biofilm-associated infections. Combine with standard antibiotic protocols.
How to Calculate LL-37 Dose Per Weight
Weight-based dosing: approximately 1 mcg/kg body weight for systemic injection. 70 kg person = 70 mcg base dose. Can titrate 50–100 mcg based on response. Local/topical dosing less dependent on weight—tissue application matters more. Always verify with supplier calculations and adjust based on peptide concentration.
Dose Escalation & Titration Protocols
Conservative start: 50 mcg for first injection, assess tolerance for 3–5 days. Week 1: 50 mcg 3x weekly. Week 2–4: 75 mcg 3x weekly. Week 5+: 100 mcg or maintain at effective dose. For topical: start 100 mcg daily, increase to 200–500 mcg if tolerance good. Titrate slowly over 2–4 weeks. Stop if adverse effects emerge.
Overdose Concerns & Safety Limits
LL-37 toxicity occurs above 75 mcg/mL in some cell cultures, but this is in vitro concentration—not directly comparable to systemic doses. Typical injection doses (50–100 mcg) are well below cytotoxic thresholds after distribution. Excessive local doses (>500 mcg topical) may cause local irritation. Signs of overdose: excessive inflammation, hemolysis (if systemic at high dose), local damage. Reduce dose if adverse effects appear.
Reconstitution Ratios & Concentration
Common dilution: 1 mg LL-37 powder + 1 mL bacteriostatic water = 1 mg/mL concentration. For 100 mcg dose = 0.1 mL injection. Higher concentrations (2 mg/mL) reduce injection volume. Lower concentrations (0.5 mg/mL) easier to measure precisely. Choose concentration based on application and comfort with injection volume. Always verify with supplier specs.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →Frequently Asked Questions About LL-37
What's the typical starting dose for LL-37?
50 mcg for first injection is conservative. Most users escalate to 75–100 mcg within 2–4 weeks. Topical: start 100 mcg daily, increase based on response.
Can I increase my LL-37 dose if I'm not seeing results?
Yes, but increase slowly over weeks. Jump from 50→200 mcg at once may cause unwanted effects. Increase 25 mcg every 1–2 weeks and monitor tolerance.
Is there a maximum safe LL-37 dose?
No strict limit for systemic use, but 100–200 mcg per injection is typical maximum for safety. Topical can tolerate higher amounts (up to 500 mcg). Exceeding guidelines increases adverse effect risk.
How do I measure micrograms accurately?
Use tuberculin (1 mL) syringe marked with 0.01 mL increments. Insulin syringes (0.3 mL) have smaller markings. For syringes: 0.1 mL @ 1 mg/mL = 100 mcg. Always double-check your math and concentration.
Should I dose based on body weight?
Weight-based dosing (≈1 mcg/kg) is a guideline, not a requirement. Many users dose the same regardless of weight—50–100 mcg is standard. Individual response matters more than strict weight-based calculations.
Can I adjust my dose mid-cycle?
Yes. If no benefit by week 2–3, increase dose. If adverse effects appear, reduce. Most protocols allow dose adjustment within the 50–100 mcg range based on tolerance and response.
Conclusion
Proper dosing is critical for LL-37 efficacy and safety. Start conservatively, monitor response, and titrate based on individual tolerance. Always use quality peptide sources, maintain sterile technique, and follow medical supervision when possible. Consistency with dosing protocols ensures best long-term outcomes.